Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

ultimate dental supplies - 16728 - dental material, denture base, polymer based - this polymer used in a laboratory is for the fabrication of a denture base, it is used to place prefabricated teeth into to make a denture for a patient. it is the material used to form a complete or a removal denture.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

ultimate dental supplies - 16728 - dental material, denture base, polymer based - this is a polymetric material used for the fabrication of a denture base the portion of a complete or removable partial denture which rests on the oral mucosa.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

henry schein halas - 16728 - dental material, denture base, polymer based - this polymeric dental material is specifically used for the fabrication of a denture base (the portion of a complete or removable partial denture which rests on the oral mucosa and retains the artificial teeth.)

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.;  ;  ; clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. - capsule - 150 mg - active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency.     excipient: erythrosine gelatin indigo carmine ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin base, based on 84.5% potency. excipient: gelatin ink lactose monohydrate magnesium stearate maize starch purified talc titanium dioxide - clindamycin hydrochloride has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. 2.lower respiratory infections including bronchitis, pneumonia, emphysema and lung abscess. 3. skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. for specific skin and soft tissue infections like erysipelas and paronychia (panaritium), it would seem logical that these conditions would respond very well to clindamycin therapy. 4. bone and joint infections including osteomyelitis and septic arthritis. 5. pelvic infections including endometritis, cellulitis, vaginal cuff infection tubo-ovarian abscesses salpingitis and pelvic inflammatory disease when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. in cases of cervicitis due to chlamydia trachomatis, mono therapy with clindamycin has been shown to be effective in eradicating the organism. 6. intra-abdominal infections including peritonitis and abdominal abscess when given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. 7. septicemia and endocarditis - the effectiveness of clindamycin in the treatment of selected cases of endocarditis has been documented when clindamycin is determined to be bactericidal to the infecting organism by in vitro testing of appropriate achievable serum concentrations. 8. dental infections such as periodental abscess and periodonitis. 9. as an alternative therapy when used in combination with quinine or amodiaquine for the treatment of multi-drug resistant plasmodium falciporum infection.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 2mg/2ml solution for infusion ampoules (pfizer ltd - noradrenaline acid tartrate - solution for infusion - 1mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 4mg/4ml concentrate for solution for infusion ampoules (pfizer ltd - noradrenaline acid tartrate - solution for infusion - 1mg/1ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

dermal laboratories ltd - isopropyl myristate; liquid paraffin - cutaneous gel - 150mg/1gram ; 150mg/1gram

Izraēla - angļu - Ministry of Health

neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 200 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

Izraēla - angļu - Ministry of Health

neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 250 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

Izraēla - angļu - Ministry of Health

neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 300 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy